Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Vor Biopharma Inc. offers a high-risk, high-reward play on U.S. commercialization of telitacicept, a dual-target autoimmune drug approved in China. Complex warrant issuances and reverse stock split ...

This scheme has consistently delivered the best returns in its Mid-Cap category across . This scheme has maintained a relatively low level of volatility within its Mid-Cap category over the past 3 ...

This scheme has consistently delivered the best returns in its Small-Cap category across . This scheme has maintained a relatively low level of volatility within its Small-Cap category over the past 3 ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.